Sovaldi, Gilead Sciences’ drug for treatment of hepatitis C, ranked among the top 5 pharmaceutical expenditures for 33 states’ Medicaid programs in 2014, according to data released recently by 2 members of the Senate Finance Committee (http://1.usa.gov/1Z0I2hM).
In 14 states, Medicaid programs spent more on Sovaldi (sofosbuvir) than on any other drug, according to the new data, released by ranking member Ron Wyden (D, Ore) and Chuck Grassley (R, Iowa) (http://1.usa.gov/1O8Grl0). Because a course of treatment costs $84 000, Medicaid programs were able to treat only 2.4% of approximately 700 000 enrollees infected with hepatitis C.
Rubin R. Hepatitis C Drugs Top State Medicaid Pharmaceutical Expenditures. JAMA. 2016;315(6):549. doi:10.1001/jama.2016.0166